Alnylam Pharmaceuticals Surges on Strong Momentum as Analysts Project 45% Upside]

Alnylam Pharmaceuticals Surges on Strong Momentum as Analysts Project 45% Upside]

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) have declined 24% year-to-date through June 30, yet the company maintains strong analyst support with 21 of 29 analysts rating it a buy or strong buy, and an average price target of $436, representing roughly 45% upside from the recent closing price.

Since 2018, Alnylam has launched six RNA interference (RNAi) therapeutics, which utilize RNA interference technology to silence disease-causing genes. Here’s what’s driving analyst optimism and one key concern to consider.

Image source: Getty Images.

Rapid Revenue and Profitability Growth

First-quarter product revenue jumped 121% year-over-year to $1.04 billion, driven by its transthyretin amyloidosis (ATTR) franchise, which grew 153% to $910 million. This growth was led by Amvuttra, an injectable treatment for polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR).

The company reported EPS of $1.51 compared to a loss of $0.14 in the prior-year quarter.

Alnylam’s 2026 guidance projects combined net product revenue of $4.9 billion to $5.3 billion, representing 71% growth at the midpoint. The company is evolving from a high-burn clinical biotech into a profitable commercial entity.

Expanding Beyond Rare Diseases

While initially focused on rare orphan diseases, Alnylam’s pipeline is advancing into mainstream therapeutic markets. Recent data positions Amvuttra as a potential first-line treatment for cardiomyopathy, affecting 0.2% of the U.S. population with 40% progressing to heart failure.

In partnership with Roche Holding (OTC: RHHBY), the company has developed zilebesiran for hypertension, which affects nearly half of U.S. adults. Meanwhile, zilebesiran and nucresiran are in phase 3 trials for hypertension and ATTR respectively.

Cemdisiran, licensed to Regeneron Pharmaceuticals, is being studied in phase 3 trials for myasthenia gravis and paroxysmal nocturnal hemoglobinuria.

Alnylam’s RNAi delivery platform creates a technological moat that enables rapid replication across liver-targeted diseases with predictable clinical outcomes. The company is advancing this advantage through AI-driven research collaborations, including a strategic partnership with Inceptive Nucleics to accelerate next-generation RNAi discovery.

Valuation Concerns

Despite recent declines, the stock trades at 75 times trailing earnings, which is elevated for a biotech company. Much of the current valuation already reflects strong commercial adoption of Amvuttra. Competitive pricing pressure from companies like Pfizer and BridgeBio Pharma could pressure margins and stock performance.

Long-Term Prospects Remain Strong

At approximately 30 times forward earnings, the stock appears reasonably valued given its trajectory. The company is already profitable, shows robust revenue and earnings growth, and has multiple therapies nearing commercialization alongside a distinctive delivery platform that should support patent protection.

“The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.”

James Halley has positions in Pfizer. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, Pfizer, and Regeneron Pharmaceuticals. The Motley Fool recommends BridgeBio Pharma and Roche Holding AG. The Motley Fool has a disclosure policy.

Source link